Biodesix(BDSX) - 2025 Q4 - Annual Results

Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Exhibit 99.1 Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, CO, February 26, 2026 – Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and oper ...